Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Life Sciences
Effects Of The Combination Of Favipiravir (T-705) And Oseltamivir On Influenza A Virus Infections In Mice, D F. Smee, B L. Hurst, M H. Wong, K W. Bailey, E B. Tarbet, John D. Morrey, Y Furuta
Effects Of The Combination Of Favipiravir (T-705) And Oseltamivir On Influenza A Virus Infections In Mice, D F. Smee, B L. Hurst, M H. Wong, K W. Bailey, E B. Tarbet, John D. Morrey, Y Furuta
John D. Morrey
Favipiravir (T-705 [6-fluoro-3-hydroxy-2-pyrazinecarboxamide]) and oseltamivir were combined to treat influenza virus A/NWS/33 (H1N1), A/Victoria/3/75 (H3N2), and A/Duck/MN/1525/81 (H5N1) infections. T-705 alone inhibited viruses in cell culture at 1.4 to 4.3 µM. Oseltamivir inhibited these three viruses in cells at 3.7, 0.02, and 0.16 µM and in neuraminidase assays at 0.94, 0.46, and 2.31 nM, respectively. Oral treatments were given twice daily to mice for 5 to 7 days starting, generally, 24 h after infection. Survival resulting from 5 days of oseltamivir treatment (0.1 and 0.3 mg/kg/day) was significantly better in combination with 20 mg/kg of body weight/day of T-705 against …